Donor Derived Transmissions 2020: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC) with a Focus on COVID-19
R. M. La Hoz1, A. Agarwal1, G. Berry1, K. Dunn1, J. Goldman1, S. Ho1, M. Kittleson1, D. H. Lee1, D. J. Levine1, C. Marboe1, G. Marklin1, S. Pouch1, R. Razonable1, S. Taimur1, H. Te1, A. Woolley1, C. Fox2, C. Jett2, S. Booker2, D. K. Klassen2, L. Danziger-Isakov1
1OPTN DTAC, Richmond, VA, 2UNOS, Richmond, VA
Meeting: 2022 American Transplant Congress
Abstract number: 159
Keywords: Infection
Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: COVID-19 Infections Part 1: All Organs
Session Type: Rapid Fire Oral Abstract
Date: Sunday, June 5, 2022
Session Time: 5:30pm-7:00pm
Presentation Time: 5:40pm-5:50pm
Location: Hynes Ballroom B
*Purpose: The OPTN DTAC, a multidisciplinary group, evaluates potential donor derived transmission events (PDDTE) to assess the likelihood of disease transmission.
*Methods: Retrospective study of PDDTE cases reported to the OPTN between 01/20 and 12/20. DTAC reviewed cases using a standardized classification algorithm.
*Results: During 2020, there were 18,318 donors and 37,583 unique recipients. DTAC reviewed 261/427 PDDTE from donor (111) or recipient (150) findings. 64/261 (25%) donors had proven/probable transmission (P/P Tr) of infection, malignancies or other to 84/206 (41%) exposed recipients [figure]. 12 involved living donors. Infection occurred with 44/64 P/P cases affecting 63 recipients. Viruses were most frequent P/P infections with 29 recipients having P/P Tr from 19 donors. COVID-19 PDDTE represented 11% (29/261) of all cases reviewed involving 29 donors and 15 lung and 76 non-lung recipients. One lung recipient had P/P Tr and died; none of the non-lung recipients developed P/P Tr. For bacteria, 20 recipients had P/P Tr from 14 donors. Deaths from infection (N=10) occurred at a median of 20 days (5-89 days). Attributable death was highest for fungal (4/12, 33%) and bacterial infections (6/20, 30%). 7 donors with malignancies were classified as P/P impacting 15 recipients with 1 attributable death. 53 non-infection, non-malignancy PDDTE were reported; 13 resulted in P/P Tr to 14 recipients.
*Conclusions: Although P/P events remain rare, 1/4 reviewed cases resulted in unanticipated P/P Tr. This is a conservative estimate due to passive reporting and empiric interventions. In 29 COVID-19 PDDTE only 1 lung recipient had P/P Tr. The DTAC continues to evaluate PDDTE to maximize organ use and minimize the risk of transmission.
To cite this abstract in AMA style:
Hoz RMLa, Agarwal A, Berry G, Dunn K, Goldman J, Ho S, Kittleson M, Lee DH, Levine DJ, Marboe C, Marklin G, Pouch S, Razonable R, Taimur S, Te H, Woolley A, Fox C, Jett C, Booker S, Klassen DK, Danziger-Isakov L. Donor Derived Transmissions 2020: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC) with a Focus on COVID-19 [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/donor-derived-transmissions-2020-analysis-of-the-optn-ad-hoc-disease-transmission-advisory-committee-dtac-with-a-focus-on-covid-19/. Accessed December 3, 2024.« Back to 2022 American Transplant Congress